

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:



Practitioners associated with the Customer Number:

051957

OR



Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

051957


OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

Assignee Name and Address:

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612**A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.****SIGNATURE of Assignee of Record**

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	June 9, 2009
Name	Debra D. Condino	Telephone	(714) 246-2388
Title	Assistant Secretary		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Allergan, Inc.Application No./Patent No.: 5,474,979 Filed/Issue Date: December 12, 1995Entitled: NONIRRITATING EMULSIONS FOR SENSITIVE TISSUEALLERGAN, INC., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 013933, Frame 0496, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Debra D. Condino

Signature

10/24/2011

Date

Debra D. Condino

Printed or Typed Name

714.246.2388

Telephone Number

Assistant Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES
PATENT AND
TRADEMARK OFFICE

RECEIVED

SEP 09 2003

SEPTEMBER 04, 2003

PTAS

Deputy Under Secretary of Commerce For Intellectual Property and
Deputy Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

ALLERGAN, INC.
MARTIN A. VOET (T2-7H)
2525 DUPONT DRIVE
IRVINE, CA 92612



102420498A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/14/2003

REEL/FRAME: 013933/0496
NUMBER OF PAGES: 41

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ALLERGAN SALES, LLC (FORMERLY IN
THE NAME OF VISION
PHARMACEUTICALS L.P.

DOC DATE: 04/04/2003

ASSIGNOR:

ALLERGAN- WITH WACO OR DUPONT
ADDRESS

DOC DATE: 04/04/2003

ASSIGNEE:

ALLERGAN, INC.
25254 DUPONT DRIVE
IRVINE, CALIFORNIA 92612

SERIAL NUMBER: 06496753
PATENT NUMBER: D279357

FILING DATE: 05/20/1983
ISSUE DATE: 06/25/1985

SERIAL NUMBER: 06825309
PATENT NUMBER: 4786651

FILING DATE: 02/03/1986
ISSUE DATE: 11/22/1988

APPENDIX "A" (Page 7)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,580,892	Garst; et al.	17014
5,708,015	Garst; et al.	17014-DIV
5,476,872	Garst; et al.	17018
5,474,979	Ding; et al.	17025
5,981,607	Ding; et al.	17025-CIP2
5,564,596	Meadows; et al.	17026-FWC
5,891,911	Adorante; et al.	17030
5,534,641	Song; et al.	17031
5,698,700	Song; et al.	17031-DIV
5,847,160	Song; et al.	17031-DIV2
5,519,040	Chow; et al.	17035
5,498,795	Song; et al.	17036
5,799,837	Firestone; et al.	17039-CIP
5,731,337	Munk; et al.	17053-FWC
6,150,389	Munk; et al.	17053-FWC-CIP
6,319,935	Munk; et al.	17053-FWC-CIP- CON
5,677,327	Gil; et al.	17056
5,521,183	Woodward; et al.	17057
5,659,042	Gillett; et al.	17059
5,616,712	Teng; et al.	17079
5,602,143	Achim H. Krauss	17081
5,652,236	Achim H. Krauss	17081-CIP
5,559,151	Adorante; et al.	17082
5,705,530	Adorante; et al.	17082-CON
5,866,605	Adorante; et al.	17082-CON2
5,824,685	Campochiaro; et al.	17083
	(only that portion assigned to Allergan Waco)	
6,071,924	Campochiaro; et al.	17083-CON
	(only that portion assigned to Allergan Waco)	
6,075,032	Campochiaro; et al.	17083-CIP
	(only that portion assigned to Allergan Waco)	
6,372,753	Campochiaro; et al.	17083-CIP-CON
	(only that portion assigned to Allergan Waco)	
6,025,388	Nagpal; et al.	17084
6,369,100	Nagpal; et al.	17084-DIV
5,675,033	Vuligonda; et al.	17085
5,917,082	Vuligonda; et al.	17085-CIP
5,663,367	Vuligonda; et al.	17085-DIV2